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Purpose or Objective: Neoadjuvant chemoradiation(nCRT) 
has been represented as the standard treatment for locally 
advanced rectal cancer(LARC). Tumor pathological responses 
and radiotherapeutic sensitivity alter variously. We aimed to 
explore the predict value of serum circulating miRNAs, which 
have already been certificated as potential therapeutic 
predictors in many cancers for the pathological responses and 
radiosensitivity after nCRT in LARC patients. 
 
Material and Methods: Six fresh tumor biopsy samples of T3-
4/N+ rectal cancer patients were collected before any 
treatments and these samples were classified as radiation 
sensitive and resistant groups according to the postoperative 
pathological analysis assessed by Mandard TRG scale(3 
samples of TRG1 vs 3 samples of TRG4). The two groups were 
strictly matched by clinical features. miRNAs expression 
profile of the two groups were analyzed by microarray. 
Predictive value of radiotherapeutic sensitivity of the 
candidated miRNAs was further validated by 160 serum 
samples of LARC patients.  
 
Results: 19 miRNAs were identified to have different 
expression profile between radiation sensitive and resistant 
groups by microarray analysis (p<0.05). Among these miRNAs, 
nine miRNAs were down-regulated and ten were up-regulated 
in radiation sensitive group. miR-345-5p was identified 
significantly correlated with radiation resistant to nCRT and 
appeared highly discrepant expression between the two 
groups (fold change>2). Low expression of miR-345-5p in 
serum predicted superior pathological responses to 
radiosensitivity after nCRT (TRG1/2) (AUC=0.69, p<0.001) and 
favorable LRFS (p=0.02). 
 
 
 
Conclusion: Serum level of miR-345-5p is associated with 
favorable pathological responses to neoadjuvant 
chemoradiotherapy and local-regional control ratio in LARC 
patients. It presents as a promising biomarker to predict the 
radiotherapy sensitivity and prognosis. 
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Purpose or Objective: To evaluate the significance of 
postoperative carcinoembryonic antigen (CEA) level as a 
predictor for tumor recurrence and as a prognostic factor for 
survival in locally advanced rectal cancer patients treated 
with preoperative concurrent chemoradiation followed by 
curative surgery 
 
Material and Methods: Total 1559 rectal cancer patients 
staged with cT3-4N0-2M0 received pelvic preoperative 
chemoradiotherapy (CRT) 50.4 Gy in 28 fractions followed by 
total mesorectal excision (TME). CEA levels were measured 
before CRT and after surgery. Clinicopathologic factors which 
could be associated with tumor recurrence and survival were 
analyzed. 
 
Results: The cumulative probability of the tumor recurrence 
showed a steep increase with a cutoff value of 2.5 ng/mL for 
postoperative CEA, and the gradient decreased as 
postoperative CEA levels increased above 2.5 ng/mL. After 
median follow-up time of 46.7 months, patients with 
postoperative CEA level of > 2.5 ng/mL had significantly 
lower relapse-free survival (75.6% vs. 65.2%, p<0.001) and 
overall survival (88.3% vs. 78.1%, p<0.001) at 5 years than 
patients with CEA level of ≤2.5 ng/mL. In the multivariate 
analysis, postoperative CEA level is the only significant 
prognostic factors of relapse free survival (HR=1.561 and 95% 
CI=1.221-1.996, p<0.001) and overall survival (HR=2.073 and 
95% CI=1.498-2.869, p<0.001). Increased pre-CRT CEA level is 
not a significant prognostic factor with consideration of 
postoperative CEA in multivariate analysis. The postoperative 
CEA level above 2.5 ng/ml is a significant predictor for 
distant recurrence (OR=1.689 and 95% CI=1.188-2.402, 
p=0.004), but not for local recurrence (OR=0.776 and 95% 
CI=0.389-1.549, p=0.472). 
 
Conclusion: Postoperative CEA level above 2.5 ng/ml is a 
predictor for tumor recurrence and a negative prognostic 
factor for survival in rectal cancer patients who received 
preoperative CRT and curative surgery. Physician can 
consider intense surveillance after curative resection in these 
patient. 
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Purpose or Objective: Anal cancers are treated by definitive 
chemoradiotherapy of the primary tumor and pelvic nodes. 
Although survival is high (5y 75%), locoregional recurrence 
occurs in 24% of patients. Patients are mostly treated with 
IMRT and VMAT, and therefore precise dose delivery is 
important. For target volume delineation typically either PET 
or MRI is used together with planning CT, but practice varies 
between institutions. In the current work, we aim to 
investigate the variability between imaging modalities and 
oncologists with respect to target volume delineation based 
on either PET/CT or MRI/CT information. 
 
Material and Methods: Twenty patients with anal cancer 
referred to chemoradiotherapy were prospectively included. 
Written informed consent was obtained from all patients and 
the regional ethics committee approved the study. Prior to 
therapy, patients underwent a planning CT scan, a PET/CT 
scan with 18FDG and T2 and diffusion weighted MRI scans at a 
3T scanner. At the treatment planning station (Varian 
Eclipse), all images where co-registered to the planning CT 
scan. Three oncologists delineated the Gross tumor volume 
(GTV) independently of each other twice for each patient, 
once with medical records and images blinded for MRI 
information, and once blinded for PET information. The CT 
image information was always available. A randomization 
scheme of the order of the anonymized patients was used 
during delineation to minimize intra-observer bias. All 
volumes were exported from the treatment planning system, 
analyzed by calculating the DICE coefficients and compared 
with the Wilcoxon Signed-rank test. 
 
Results: The median volume of the GTV was respectively 
27.5 cm3 and 31.0 cm3 for PET and MRI, and there was a high 
correlation (r=0.94) between the volumes. The DICE 
coefficient (minimum, median, maximum) was 0.43, 0.81, 
0.93 and 0.50, 0.75, 0.89 for PET and MRI. These DICE 
distributions were significantly different (P=0.03). Half of the 
patients with low DICE (<0.7) for PET, also gave low DICE for 
MRI, this indicated difficulties with delineation irrespective 
of imaging modality. For inter-modality comparison (PET to 
MRI for same observer), the DICE coefficient was 0.31, 0.75, 
0.92, with a significant difference in distribution relative to 
the inter-observer distribution. 
 
 
Conclusion: PET and MRI produced similar GTV volumes for 
radiotherapy planning of anal cancer. However, PET has a 
significantly lower inter-observer variability in terms of the 
DICE coefficients. Still, the deviations between PET and MRI 
were not substantial and may not translate into clinically 
meaningful differences. This is also supported by the 
relatively high inter-modality DICE coefficients. Thus, 
radiotherapy target delineation for anal cancer is performed 
quite consistently among observers and is not strongly 
dependent on whether PET or MRI is used. 
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Purpose or Objective: In locally advanced rectal cancer 
(LARC), further advances in individualised treatment 
approaches require identification of robust biomarkers. 
Although metabolic reprogramming has been regarded 
essential for cancer cell proliferation, the systematic 
characterisation of activated metabolic pathways in 
aggressive cancer is scarce. Hence, by recognising the link 
between altered tumour metabolism and disease 
aggressiveness, we aimed to identify associations between 
pretreatment tumour metabolic profiles and therapeutic 
outcome in LARC. 
 
Material and Methods: Tumour metabolic profiles were 
acquired from 54 LARC patients, receiving induction 
neoadjuvant chemotherapy followed by long-course 
chemoradiotherapy and surgery, by using high-resolution 
magic angle spinning magnetic resonance spectroscopy. 
Metabolite concentrations were correlated to TNM and 
presence of disseminated tumour cells (DTC) at time of 
diagnosis, and to ypTN and tumour regression grade (TRG) 
following the neodjuvant treatment. All patients had either 
reached 5 years of follow-up or were scored with a 
progression-free survival (PFS) event at time of analysis. The 
performance of metabolite concentrations in prediction of 
PFS was assessed by receiver operating characteristic curves. 
Univariate Cox regression assessed associations between 
selected variables and PFS; those being significant were 
entered into multivariate analysis. Survival differences were 
assessed by the Kaplan-Meier method. 
 
Results: Pretreatment tumour metabolite concentrations 
showed no significant associations to TNM, DTC, ypTN or TRG. 
In univariate regression analysis, high concentrations of 
glycine, creatine and myo-inositol were significantly 
associated to poor PFS, with distant metastasis to the lung 
and/or liver being the main PFS event (87.5% of events). 
When separating patients above and below the identified cut-
off concentrations the respective estimated 5-year PFS were 
85% and 50% for glycine, 74% and 29% for creatine and 81% 
and 50% for myo-inositol. In multivariate analysis, high 
glycine concentration remained most significantly associated 
to poor PFS (hazard ratio = 4.4, 95% confidence interval = 
1.4–14.3, p = 0.008). 
 
Conclusion: High tumour glycine concentration was 
identified as adverse prognostic factor for PFS in LARC. In a 
patient population treated with curative intent but with 
metastatic disease as main PFS event these results motivate 
further investigations of glycine as early predictor of 
metastatic progression and as potential therapeutic target. 
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